April 15, 2019

San Francisco, CA, April 1, 2019 – Geom Therapeutics, Inc., a privately held biopharmaceutical company focused on the development of novel antibiotics for multidrug-resistant (MDR) gram-negative infections, today announced upcoming data presentations at the 29th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in Amsterdam, Netherlands from April 13 to 16, 2019.  One poster and one oral presentation demonstrating the mechanism of action and efficacy driver of GT-055, a novel dual-action beta-lactamase inhibitor, in combination with GT-1, a siderophore cephalosporin with a novel uptake mechanism, have been accepted for presentation.

Dirk Thye, M.D., Executive Chairman of Geom Therapeutics, Inc., said, “GT-1 and GT-055 are intended for the treatment of multidrug-resistant gram-negative infections, including infections caused by species of Enterobacteriaceae, Acinetobacter and Pseudomonas. Infections caused by these multidrug resistant organisms are among the mos...

Please reload

Recent Posts
Please reload

Archive
Please reload

Site map:

Contact Us